Study of rSIFN-co for Patients With Advanced Solid Tumors

The initial cohort will be 3 subjects. Escalation to the next dose will continue unless a
subject experiences a DLT, at which time a cohort will be expanded to up to 6 subjects.
Provided there is only one DLT in that cohort, the dose will be escalated. However, if there
are 2 DLTs in that cohort of up to 6 subjects, previous dose level will be expanded to total
of 9 subjects.

If none of the dose levels are acceptable at study completion (i.e., >33% of subjects
experiencing a DLT), an OD will not be identified, and the drug does not warrant further
investigation.

Inclusion Criteria

1. Male or female ≥ 18 years of age

2. Diagnosis of advanced solid tumors limited to: melanoma, kidney cancer, lung cancer,
colorectal carcinoma, prostate cancer, and neuroendocrine tumor progressing on
standard therapy.

3. Has measurable disease, defined as at least 1 tumor that fulfills the criteria for a
target lesion according to RECIST 1.1.

4. Prior systemic chemotherapy, immunotherapy (including interferon), or biological
therapy, radiation therapy and/or surgery for resection of solid tumor (limited to:
melanoma, kidney cancer, lung cancer, colorectal carcinoma, prostate cancer, and
neuroendocrine tumor) are allowed.

5. Has an Eastern Cooperative Oncology Group (ECOG) performance status of ≤1.

6. Has adequate hepatic function defined as total bilirubin ≤1.5 mg/dL, unless associated
with hepatobiliary metastases or Gilbert syndrome, then total bilirubin or ≤ 2 ULN.
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 2.5 × upper
limit of normal (ULN) or ≤ 5 x ULN for subjects with known hepatic metastases.

7. Has adequate renal function defined as serum creatinine or ≤ 1.5 × ULN and creatinine
clearance or ≥ 40 ml/min.

8. Has adequate bone marrow function defined as a hemoglobin > 9 g/dL, absolute
neutrophil count (ANC) ≥1.5 ×10⁹/L , and platelet count ≥100,000/mm³. For subjects who
received chemotherapy for melanoma just prior to screening for the study subject needs
to have a hemoglobin > 9 g/dL, absolute neutrophil count (ANC) >2 × 10⁹/L, and
platelet count ≥100,000/mm³.

9. Must be willing and able to comply with study visits and procedures.

10. Has read, understood and signed the informed consent form (ICF) approved by the
Institutional Review Board/Independent Ethics Committee (IRB/IEC).

11. Women of childbearing potential (WOCP) must not be pregnant (confirmed by a negative
pregnancy test, with a serum beta-HCG with a sensitivity of 50 mIU/ml within 7 days of
study treatment) or breast-feeding. In addition, a medically acceptable method of
birth control must be used such as an oral, implantable, injectable, or transdermal
hormonal contraceptive, an intrauterine device (IUD), use of a double barrier method
(condoms, sponge, diaphragm, or vaginal ring with spermicidal jellies or cream), or
total abstinence during the study and at least one month after the last dose of study
drug. Women who are postmenopausal for at least 1 year or surgically sterile
(bilateral tubal ligation, bilateral oophorectomy, or hysterectomy) are not considered
to be WOCP.

12. Men who are not surgically or medically sterile must agree to use an acceptable method
of contraception. Male subjects with female sexual partners who are pregnant, possibly
pregnant, or who could become pregnant during the study must agree to use condoms from
the date of the first dose of study drug through at least one month after the last
dose of study drug. Total abstinence for the same study period is an acceptable
alternative.

Exclusion Criteria

1. Chemotherapy, immunotherapy (including interferon), or biological therapy, radiation
therapy and/or surgery within 4 weeks prior to first dose of study drug.

2. Prior mTOR inhibitor therapy within 4 weeks prior to first dose of study drug.

3. Has a history of autoimmune disorders, including uncontrolled diabetes ("uncontrolled"
defined as Hemoglobin A1c ≥ 9% in 28 days prior to study).

4. Chronic use of steroid therapy.

5. Has a history of epilepsy, depression or other psychiatric disorders.

6. Has a history of an arterial thromboembolic event within the prior six months
including cerebrovascular accident, transient ischemic attack, myocardial infarction,
or unstable angina.

7. Has uncontrolled human immunodeficiency virus (HIV) (defined as HIV RNA >500 copies/ml
and CD4+ count<200/mm³ on antiretroviral therapy)infection, or hepatitis B (defined as
ALT > 1 x ULN, and HBV DNA >2000 IU/ml), or hepatitis C (defined as ALT > 1 x ULN,
persistent viremia on antiviral therapy) infections.

8. Has a history of blood clots, pulmonary embolism, or deep vein thrombosis unless
controlled by anticoagulant treatment (patient must be on stable dose for 2 weeks).

9. Prior allogeneic bone marrow or organ transplantation.

10. Has any clinically significant infection, i.e., any acute viral, bacterial, or fungal
infection that requires specific treatment (anti-infective treatment has to be
completed ≥ 7 days prior to study entry).

11. Has any other severe, uncontrolled medical condition, including unstable congestive
heart failure (Stage III-IV of the New York Heart Association Functional
Classification) or has a known or suspected allergy to the study drug or any study
drug component.

12. Pregnant or breastfeeding - interferon products (e.g., Infergen®) is Pregnancy
Category C, (i.e., animal reproduction studies have shown an adverse effect on the
fetus and there are no adequate and well-controlled studies in humans.). Confirmation
that the subject is not pregnant must be established by a negative serum beta-human
chorionic gonadotropin (β-HCG) pregnancy test result obtained during screening.
Pregnancy testing is not required for post-menopausal or surgically sterilized women.

13. Subject has received other investigational drugs within 14 days prior to first dose of
study drug.

14. Other severe acute or chronic medical or psychiatric conditions or laboratory
abnormality that may increase the risk associated with study participation or
investigational product administration or may interfere with the interpretation of
study results and, in the judgment of the investigator, would make the subject
inappropriate for enrollment in this study.

15. Abnormalities on 12-lead electrocardiogram (ECG) considered by the investigator to be
clinically significant or baseline prolongation of the rate-corrected QT interval
(e.g., repeated demonstration of QTc interval > 480 milliseconds).

16. Presence of any non-healing wound, fracture, or ulcer within 28 days prior to the
first dose of study drug.

17. Has any condition that, in the opinion of the investigator, might jeopardize the
safety of the subject or interfere with protocol compliance.

18. Has any mental or medical condition that prevents the subject from giving informed
consent or participating in the trial